Editas Medicine (EDIT) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Join SI Premium – FREE
Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.84), $0.09 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $3.67 million versus the consensus estimate of $4.13 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
- OPENLANE, Inc. (OPLN) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
